Advertisement

Cancer Immunology, Immunotherapy

, Volume 57, Issue 11, pp 1695–1703 | Cite as

Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors

  • Hyun-Il Cho
  • Guilian Niu
  • Norma Bradley
  • Esteban CelisEmail author
Symposium Paper

Abstract

Background

Vaccines capable of inducing CD8 T cell responses to antigens expressed by tumor cells are considered as attractive choices for the treatment and prevention of malignant diseases. Our group has previously reported that immunization with synthetic peptide corresponding to a CD8 T cell epitope derived from the rat neu (rNEU) oncogene administered together with a Toll-like receptor agonist as adjuvant, induced immune responses that translated into prophylactic and therapeutic benefit against autochthonous tumors in an animal model of breast cancer (BALB-neuT mice). DNA-based vaccines offer some advantages over peptide vaccines, such as the possibility of including multiple CD8 T cell epitopes in a single construct.

Materials and methods

Plasmids encoding a fragment of rNEU were designed to elicit CD8 T cell responses but no antibody responses. We evaluated the use of the modified plasmids as DNA vaccines for their ability to generate effective CD8 T cell responses against breast tumors expressing rNEU.

Results

DNA-based vaccines using modified plasmids were very effective in specifically stimulating tumor-reactive CD8 T cell responses. Moreover, vaccination with the modified DNA plasmids resulted in significant anti-tumor effects that were mediated by CD8 T cells without the requirement of generating antibodies to the product of rNEU.

Conclusions

DNA vaccination is a viable alternative to peptide vaccination to induce potent anti-tumor CD8 T cell responses that provide effective therapeutic benefit. These results bear importance for the design of DNA vaccines for the treatment and prevention of cancer.

Keywords

DNA vaccines HER2/neu CD8 T cells Breast cancer Animal models 

Abbreviations

rNEU

rat neu oncogene

TLR

Toll-like receptor

Notes

Acknowledgments

This work was supported by NIH grants R01CA103921, R01CA80782, and P50CA91956.

References

  1. 1.
    Buteau C, Markovic SN, Celis E (2002) Challenges in the development of effective peptide vaccines for cancer. Mayo Clinic Proc 77:339–349CrossRefGoogle Scholar
  2. 2.
    Guy C, Webster M, Schaller M, Parsons T, Cardiff R, Muller W (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89:10578–10582PubMedCrossRefGoogle Scholar
  3. 3.
    Lucchini F, Sacco MG, Hu N, Villa A, Brown J, Cesano L, Mangiarini L, Rindi G, Kindl S, Sessa F, et al (1992) Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice. Cancer Lett 64:203–209PubMedCrossRefGoogle Scholar
  4. 4.
    Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini PL, Colombo MP, Forni G (1998) Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 188:589–596PubMedCrossRefGoogle Scholar
  5. 5.
    Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Curcio C, Lollini PL, Musiani P, Forni G, Cavallo F (2004) Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 64:2858–2864PubMedCrossRefGoogle Scholar
  6. 6.
    Rovero S, Amici A, Carlo ED, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, Landuzzi L, Colombo MP, Giovarelli M, Musiani P, Forni G (2000) DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165:5133–5142PubMedGoogle Scholar
  7. 7.
    Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E (2007) Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 67:1326–1334PubMedCrossRefGoogle Scholar
  8. 8.
    Lachman LB RX, Kremer RH, Ozpolat B, Kiriakova G, Price JE (2001) DNA vaccination against neu reduces breast cancer incidence and metastasis in mice. Cancer Gene Ther 8:259–268PubMedCrossRefGoogle Scholar
  9. 9.
    Miller FR, Miller BE, Heppner GH (1983) Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 3:22–31PubMedGoogle Scholar
  10. 10.
    Spadaro M, Ambrosino E, Iezzi M, Di Carlo E, Sacchetti P, Curcio C, Amici A, Wei WZ, Musiani P, Lollini PL, Cavallo F, Forni G (2005) Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin Cancer Res 11:1941–1952PubMedCrossRefGoogle Scholar
  11. 11.
    Shimonkevitz R, Kappler J, Marrack P, Grey H (1983) Antigen recognition by H-2-restricted T cells. I. Cell-free antigen processing. J Exp Med 158:303–316PubMedCrossRefGoogle Scholar
  12. 12.
    Piechocki MP, Pilon SA, Wei WZ (2002) Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J Immunol Methods 259:33–42PubMedCrossRefGoogle Scholar
  13. 13.
    Spadaro M, Ambrosino E, Iezzi M, Di Carlo E, Sacchetti P, Curcio C, Amici A, Wei W-Z, Musiani P, Lollini P-L, Cavallo F, Forni G (2005) Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin Cancer Res 11:1941–1952PubMedCrossRefGoogle Scholar
  14. 14.
    Gallo P, Dharmapuri S, Nuzzo M, Maldini D, Cipriani B, Forni G, Monaci P (2007) Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice. Int J Cancer 120:574–584PubMedCrossRefGoogle Scholar
  15. 15.
    Rolla S, Nicolo C, Malinarich S, Orsini M, Forni G, Cavallo F, Ria F (2006) Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 177:7626–7633PubMedGoogle Scholar
  16. 16.
    Curcio C, Di Carlo E, Clynes R, Smyth MJ, Boggio K, Quaglino E, Spadaro M, Colombo MP, Amici A, Lollini PL, Musiani P, Forni G (2003) Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 111:1161–1170PubMedGoogle Scholar
  17. 17.
    Whitton JL, Sheng N, Oldstone MB, McKee TA (1993) A “string-of-beads” vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J Virol 67:348–352PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Hyun-Il Cho
    • 1
  • Guilian Niu
    • 1
  • Norma Bradley
    • 1
  • Esteban Celis
    • 1
    Email author
  1. 1.Immunology/Immunotherapy ProgramH. Lee Moffitt Cancer CenterTampaUSA

Personalised recommendations